"This means that, on average, half of the patients receiving Trodelvy lived for approximately 11.8 months, and half of them lived without their cancer progressing for about 4.8 months"
_____
Cytodyn:
"The Company has also now confirmed survival outcomes in a group of patients with mTNBC and four prior lines of treatment who are alive more than 48 months after receiving leronlimab. This includes four patients who currently identify as having no evidence of ongoing disease ......* and a fifth patient who is alive with stable disease *

Said after the 36+ news:
What other data is there & our "worst" LL data, will be far better than Trodelvy's best data.

4.8 months Vs "more than 48 months".

Wow...another stunner